Uric acid is associated with cognitive impairment in the elderly patients receiving maintenance hemodialysis—A two‐center study

Abstract

Background Elevated serum uric acid (SUA) has been associated with vascular cognitive impairment (CI) in the elderly. However, its relationship with cognitive function in the elderly patients receiving maintenance hemodialysis (MHD) has not yet been elucidated. Objective The cognitive impairment is prevalent in MHD patients. Various insults may contribute to cognitive impairment in patients with MHD. The aim of this study was to investigate the relationship between SUA and CI in the elderly patients receiving MHD. Methods A total of 180 elderly MHD subjects from two hospitals were enrolled in our study. Cognitive function domains were evaluated by MMSE at the beginning of the trial. Demographic and clinical characteristics were collected and recorded. Results The subjects were stratified into quartiles according to SUA level. Demographic and clinical characteristics such as age, gender, smoking habit, education year, blood pressure (BP), hemoglobin, albumin, blood glucose (BG), total cholesterol (TC), triglycerides (TG), high‐density lipoprotein cholesterol (HDL), low‐density lipoprotein cholesterol (LDL), blood urea nitrogen (BUN), and serum creatinine (Scr) did not differ dramatically among groups (p > .05). The Q1 group showed the highest MMSE scores, and the Q4 group showed the lowest MMSE sores (p < .05). There was a negative correlation between SUA and MMSE scores (r = −.307, p = .014), and this correlation was independent of demographic and clinical characteristics. Conclusions Elevated SUA maybe contributes to CI in the elderly MHD patients. SUA level is independent risk for the CI in the elderly MHD patients.

Association of Serum FAM19A5 with Cognitive Impairment in Vascular Dementia

“…The highest score on the MMSE scale is 30, mainly evaluating orientation, writing, registration, visual construction, recording, and other items related to cognitive function. Cognitive impairment is defined as a score of less than 24 by the investigators, who were blinded to the subjects' baseline clinical characteristics [ 18 ].…”

Serum CCL21 as a Potential Biomarker for Cognitive Impairment in Spinal Cord Injury

“…CCL2 antibody is a purchased commercial reagent (Abcam, MA, USA). The steps of ELISA refer to previous reports and reagent instructions [ 16 ]. Record the OD at 450 nm under a spectrophotometer.…”

Association between Serum IL-37 and Spinal Cord Injury: A Prospective Observational Study

“…The ELISA experiment uses the commercialized Human IL-37 ELISA Kit (Abcam, Cambridge, MA, USA). The experimental procedures of ELISA are based on the reagent instructions and previous reports [ 12 ]. The experimental method is as follows: add 100 μ L standard or sample to appropriate wells incubated at 37°C for 90 minutes; discard plate content and then add 100 μ L biotinylated antibody into all wells incubated at 37°C for 60 minutes.…”